Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKang‐Yi SuLRLee RyanAMAlyssa Massa

Discussion

Loading...

Member takes

Overview

Preclinical findings demonstrate dual-CAR T cells reduce tumor growth in AML models, indicating promising safety and efficacy profile.

Key Points

  • This study assesses the efficacy of Tim-3/CD70 dual-targeting CAR T cells against acute myeloid leukemia (AML).
  • Immunophenotyping of bone marrow samples from AML patients and controls
  • Development of second-generation CARs targeting Tim-3 and CD70
  • Single cell RNA sequencing to analyze T cell response
  • Evaluation of tumor growth inhibition in syngeneic mouse models
  • Higher expression of Tim-3 and CD70 on AML cells confirmed by immunophenotyping
  • Dual-CAR T cells eliminated tumor cells in vitro and in vivo, overcoming antigen-negative escape
  • Dual-CAR T cells showed improved control of tumor growth compared to single-CAR T cells
  • Transient pancytopenia noted post-therapy but linked to irradiation, with no sustained toxicity observed

Cite This Study

Su et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d466https://doi.org/10.1182/blood-2025-2345
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia2025
  2. 2A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model2025
  3. 3CD4-Targeted CAR-Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia 22246872026
  4. 4Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting2025 · 12 citations
  5. 5Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model2024 · 10 citations